SEMPER PARATUS ACQU -CW26 (TVGNW) Stock News

USA - NASDAQ:TVGNW -

0.049 USD

0 (0%)

Last: 10/10/2025, 9:01:01 PM

Technical Analysis

TVGNW Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

16 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

18 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

18 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

22 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

22 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN MSFT

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion